Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Table 1 FDA-approved ICI mAbs on the market

ICI types	mAb	Disease	Refs
aPD-1	Pembrolizumab	NSCLC¹, HNSCC², HCC³, RCC⁴, SCLC⁵, Melanoma	[49]
	Nivolumab	CRC⁶, HNSCC, SCLC, HCC, cHL⁷, RCC, NSCLC	[6]
	Cemiplimab	cSCC⁸	[12]
	Atezolizumab	MCC⁹, NSCLC, Urothelial carcinoma
	Avelumab	Gastric cancer
	Durvalumab	Urothelial carcinoma, NSCLC
aCTLA-4	Ipilimumab	CRC, RCC, Melanoma
aLAG-3, aPD-1	Relatlimab, Nivolumab	Melanoma	[50]

1. Colorectal cancer, 2. Head and neck squamous cell carcinomas, 3. Hepatocellular carcinoma, 4. Renal cell carcinoma, 5. Small-cell lung carcinoma, 6. Colorectal cancer, 7. Classic hodgkin lymphoma 8. Cutaneous squamous cell carcinoma, 9. Merkel cell carcinoma

ISSN: 1477-3155